A comparative study of the efficacy of ceftazidime versus cefazolin and tobramycin in patients with acute exacerbations of chronic bronchitis.

Fifty-nine adult patients have entered this study. The initial pathogens were eradicated from the infection sites and all except two of the patients who were assessed clinically in the ceftazidime group and 4 cases in the comparative group were cured or improved. No adverse reactions were connected to ceftazidime or to tobramycin and cefazolin.

Trial of ceftazidime efficacy in respiratory infections at two dose levels.

A dose-ranging clinical trial of ceftazidime was carried out in patients with respiratory infections. Patients were randomly allocated to receive either 500 mg or 1 g doses of ceftazidime twice-daily intravenously. The organisms isolated from sputum were eradicated in 23 cases, and in 18 cases within 3 days. Five bacteriological failures were found during ceftazidime treatment (2 cases were not assessable), but only 2 of these patients had not clinically improved. There was no significant difference between the two dose regimes. The only adverse reaction was an allergic rash, occurring on the third day of treatment. This rash subsided rapidly on withdrawal of ceftazidime.

[Silicotuberculosis in Austria and the industrial injuries act (author's transl)]. / Die Silikotuberkulose in Osterreich aus versicherungsmedizinischer Sicht.

The case material comprising all persons who developed silico-tuberculosis since it was listed as an occupational disease almost 50 years ago is analysed. The relationship between various occupations and the incidence of silicosis is reviewed with special reference to the most exposed group: the wokers in the granite quarries of Upper Austria. The changes in the clinical picture of the lesion, legal aspects, diagnostic difficulties in distinguishing between silicosis with or without complicating tuberculosis are discussed.

[Effect of fominoben on ventilation, oxygen uptake and blood gases in patients with obstructive ventilation disorders]. / Wirkung von Fominoben auf Ventilation, Sauerstoffaufnahme und Blutgase bei Patienten mit obstruktiver Ventilationsstörung

The substituted benzylamin-derivative fominoben (PB 89 Noleptan) was intravenously administered to 12 patients with chronic obstructive lung disease in order to determine, whether an analeptic action on respiration, which had been found by others in animal studies and in healthy subjects, can also be demonstrated in patients with COLD. Time ventilation showed no statistically significant change. Respiratory rate was increased for a short time, alveolar ventilation showed a slight but significant increase 35 minutes after i.v. injection of fominoben, however no significant change in the first 10 minutes after injection.--Arterial pO2 was slightly but not significantly increased in the first 10 minutes after fominoben, while the same patients showed a significant decrease of pO2 after injection of placebo. As alveolar ventilation at this time had not significantly changed, the increase in pO2 can only be explained by an improvement of regional ventilation-perfusion ratio by fominoben. -In conclusion it can be stated, that a marked stimulative action on respiration by fominoben could not be demonstrated. There was, however, no depression of respiration as it is associated with most other caugh medications. As the drug has been shown to be an excellent caugh sedative, lack of respiratory depression can be considered as a considerable advantage.

[Surgical therapy of bronchiectasy and its results (author's transl)]. / Chirurgische Therapie der Bronchiektasieerkrankungen und ihre

69 patients suffering from bronchiectasies underwent surgery at the II. Surgical Clinic of the University of Vienna from 1958 to 1972. Analysis of results revealed three groups: 1. 67% of the patients cured completely, 2. 23% significantly improved, 3. 10% no improvement. The evaluation of spirometric measurements of not improved patients showed extensive preoperative obstructive ventilation disturbance.